# A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

> **NCT05232708** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers (Diabetes Mellitus, Type 2)

## Interventions

- **DRUG:** Semaglutide B, 1.34 mg/mL
- **DRUG:** Semaglutide D, 1.0 mg/mL
- **DRUG:** Semaglutide D, 1.0 mg/mL
- **DRUG:** Semaglutide B, 1.34 mg/mL

## Key facts

- **NCT ID:** NCT05232708
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232708, "A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05232708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*